Clinical experience with the use of newer antibiotics in internal medicine
Authors:
Pavla Paterová 1; Martina Novosadová 2
Authors‘ workplace:
Ústav klinické mikrobiologie Fakultní nemocnice a Lékařská fakulta UK v Hradci Králové
1; Oddělení klinické farmacie, Nemocniční lékárna, Fakultní nemocnice Hradec Králové
2
Published in:
Vnitř Lék 2022; 68(E-6): 10-14
Category:
Review Articles
doi:
https://doi.org/10.36290/vnl.2022.085
Overview
The alarming rise in antibiotic resistance between Gram-positive and Gram-negative bacteria makes maximum use of known and available antibiotics necessary. The aim of this work is to highlight some advantages and disadvantages of antibiotics that have appeared on the market in recent years, and share clinical experience with their use in internal medicine.
Flucloxacillin is an antibiotic with a significant antistaphylococcal effect, the most significant indications of the oral form are infections of the skin and soft tissues with the causative agent of Staphylococcus aureus and streptococci. The intravenous variant of flucloxacillin is an noninferior alternative to oxacillin and can be used in severe staphylococcal infections including infective endocarditis. Contributing to the treatment of uncomplicated urinary infections are the oral antibiotics mecilinam and fosfomycin. Their advantages are wide spectrum, good tolerability and possibility to use them in pregnant woman. Other antibiotics expand the treatment options for intravenous treatment of serious infections caused by multidrug-resistant bacteria. Ceftazidime/avibactam is effective for infections caused by Pseudomonas aeruginosa and enterobacteria including producers of broad-spectrum beta-lactamase ESBL, AmpC, KPC and OXA-48. The most important advantage of ceftolozane/ tazobactam is their antipseudomonal effect, is characterized by excellent clinical efficacy even against serious infections caused by Pseudomonas aeruginosa, including some multi-resistant strains.
Keywords:
antibiotic treatment – infectious diseases
Sources
1. Summary of Product Characteristic: Flucloxacilina Azevedos, on‑ line dostupné z FLUCLOXACILINA AZEVEDOS, 500MG CPS DUR 24, Státní ústav pro kontrolu léčiv (sukl.cz)
2. Summary of Product Characteristic: Flucloxacillin FRESENIUS KABI,on‑line dostupné z FLUCLOXACILLIN FRESENIUS KABI, 2G INJ/INF PLV SOL 10, Státní ústav pro kontrolu léčiv (sukl.cz)
3. Summary of Product Characteristic: Pivinorm, on‑ line dostupné z PIVINORM, 200MG TBL FLM 9 I, Státní ústav pro kontrolu léčiv (sukl.cz)
4. Pinart M, Kranz J, Jensen K et al. Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta‑analysis, Int J Inf Dis, 2017, Vol. 58:96-109.
5. Hansen BÅ, Grude N, Lindbæk M et al. The efficacy of pivmecillinam in oral step‑down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single‑arm, uncontrolled treatment study. BMC Infect Dis 2022, 22:478.
6. Jansåker F Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review, Infect Drug Resist. 2018 May 24;11:761-771.
7. Bonkar G, Bartoletti R, Bruyére F et al. EAU Guidelines on urological infections, dostupné zhttps://uroweb.org/wp‑content/ uploads/EAU‑Guidelines‑on‑Urological‑infections- 2021.pdf
8. Gupta V, Rani H, Singla N et al. Determination of Extended‑Spectrum- β‑Lactamases and AmpC production in uropathogenic isolates of Escherichia coli and susceptibility to Fosfomycin. J Lab Physicians 2013;5(2):90–93.
9. Fajfr M, louda M, Paterová P et al. The susceptibility to fosfomycin of Gram‑negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study, BMC Urol 2017 Apr 26;17(1):33.
10. Summary of Product Characteristic: Urifos, on‑ line dostupné z URIFOS, 3G POR GRA SOL 1, Státní ústav pro kontrolu léčiv (sukl.cz)
11. Qiao LD, Zheng B, Chen S et al. Evaluation of three‑dose fosfomycin tromethamine in the treatment of patiens with urinary tract infections: an uncontrolled, open‑ label, multicentre study. BMJ Open 2013;3(12):e004157.
12. Fajfr M, Balik M, Cermakova E, Bostik P. Effective Treatment for Uncomplicated Urinary Tract Infections with Oral Fosfomycin, Single Center Four Year Retrospective Study. Antibiotics (Basel). 2020 Aug 13;9(8):511.
13. Summary of Product Characteristic: Fomicyt, on‑ line dostupné z FOMICYT, 40MG/ML INF PLV SOL 10X4G, Státní ústav pro kontrolu léčiv (sukl.cz)
14. Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin, Clinical Microbiology Reviews 2016, Vol. 29, No. 2.
15. Summary of Product Characteristic: Zerbaxa, on‑ line dostupné z www.ema.europa. eu/en/documents/product‑information/ zerbaxa‑epar‑product‑information_ cs.pdf
16. Lipový B, Hanslianová M, Kaloudova Y et al. Ceftolozan/tazobaktam v terapii multifokální infekce způsobené multirezistentním kmenem Pseudomonas aeruginosa u těžce popáleného pacienta, / Klin Farmakol Farm 2019;33(3):41–45.
17. Maraolo AE. Mazziteli M, TrecarichiEM et al. Ceftolozane/tazobactam for difficult‑to‑treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off‑ label indications, International Journal of Antimicrobial Agents, 2020; 55(3).
18. Skoglund E, Ledesma KR, Lasco TM et al. Ceftolozane/tazobactam activity against meropenemnonsusceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 Dec;11:154–155.
19. Kalil AC, Metersky ML, Klompas M et al. Management of Adults With Hospitalacquired and Ventilatorassociated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect, DiS. 2016 Sep 1;63(5):e61–e111.
20. Tamma PD, Aitken SL, Bonomo RA et al. Guidance on the Treatment of ExtendedSpectrum β‑lactamase Producing Enterobacterales (ESBL‑E), Carbapenem‑Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult‑to‑Treat Resistance (DTRP. aeruginosa) online at https://www.idsociety.org/practice‑guideline/ amrguidance/. Infectious Diseases Society of America 2022 Last updated March 7, 2022.
21. Summary of Product Characteristic: Zavicefta, on‑line dostupné z ZAVICEFTA, 2G/0,5G INF PLV CSL 10, Státní ústav pro kontrolu léčiv (sukl.cz)
22. Hladík M, Lipový H, Hanslianová M et al. Ceftazidim/avibaktam v terapii infekčních komplikací kriticky popáleného pacienta s inhalačním traumatem, Klin Farmakol Farm 2020;34(4):175-178.
23. Wiedermannová H, Zárubová P, Adámková V, et al. Ceftazidim/avibactam v léčbě gramnegativní nozokomiální sepse u nezralého novorozence, Pediatr. praxi 2020; 21(6):426-428.
24. Daikos DL, Cunha CA, Rossolini GM et al. Review of Ceftazidime‑Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa, Antibiotics 2021,10(9),1126.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2022 Issue E-6
Most read in this issue
- Evaluation of medication errors in the hospital environment
- Clinical experience with the use of newer antibiotics in internal medicine
- Therapy of immunoglonuline IgG4 related disease (IgG4-RD)
- New onset of diabetes mellitus and weight loss as a manifestation of pancreatic cancer